| Dr Tabatha Trapp Mccallum, AUD | |
|
40 Sw 12th St, C-201, Ocala, FL 34471-6525 | |
| (352) 351-3977 | |
| Not Available |
| Full Name | Dr Tabatha Trapp Mccallum |
|---|---|
| Gender | Female |
| Speciality | Qualified Audiologist |
| Experience | 14 Years |
| Location | 40 Sw 12th St, Ocala, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053622795 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | AY1616 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Professional Hearing Group Llc | 8325413677 | 10 |
News Archive
Tens of thousands of Massachusetts residents depend on home care to support their health as they age or cope with physical challenges. That care often requires close personal contact, increasing the risk of contracting COVID-19 among both home-care clients and the aides who provide their care.
Before you plop in front of the television for a day of football, pizza and beer, you might consider this: New research shows that in young adults, decades of hard-won progress in reducing the risk of heart disease appears to be stalling, as recent death rates from coronary disease remain almost unchanged in young men and may even be increasing in women.
Metal-binding agents rubbed into the skin, prescribed by some alternative practitioners for the treatment of autism, are not absorbed and therefore are unlikely to be effective at helping the body excrete excess mercury. The study by Jennifer Cohen and Michelle Ruha from Banner Good Samaritan Medical Center in the US, and their colleagues, provides evidence against the use of these treatments in children with autism.
Today, Intercell AG announced its financial results for Q2 and H1 2010.IXIARO/JESPECT sales increased significantly from EUR 2.4m in Q2 2009 to EUR 5.2m in Q2 2010 Continued focus on growing marketing and sales of product in traveler and military markets
Almirall, S.A. announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for linaclotide, an investigational guanylate cyclase-C (GC-C) receptor agonist for the treatment of irritable bowel syndrome with constipation (IBS-C). Once approved, linaclotide will be marketed in Europe under the trademark Constella®.
› Verified 4 days ago
| Provider Name | Medical Management Of Ocala Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1861651259 PECOS PAC ID: 4587619036 Enrollment ID: O20080627000296 |
News Archive
Tens of thousands of Massachusetts residents depend on home care to support their health as they age or cope with physical challenges. That care often requires close personal contact, increasing the risk of contracting COVID-19 among both home-care clients and the aides who provide their care.
Before you plop in front of the television for a day of football, pizza and beer, you might consider this: New research shows that in young adults, decades of hard-won progress in reducing the risk of heart disease appears to be stalling, as recent death rates from coronary disease remain almost unchanged in young men and may even be increasing in women.
Metal-binding agents rubbed into the skin, prescribed by some alternative practitioners for the treatment of autism, are not absorbed and therefore are unlikely to be effective at helping the body excrete excess mercury. The study by Jennifer Cohen and Michelle Ruha from Banner Good Samaritan Medical Center in the US, and their colleagues, provides evidence against the use of these treatments in children with autism.
Today, Intercell AG announced its financial results for Q2 and H1 2010.IXIARO/JESPECT sales increased significantly from EUR 2.4m in Q2 2009 to EUR 5.2m in Q2 2010 Continued focus on growing marketing and sales of product in traveler and military markets
Almirall, S.A. announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for linaclotide, an investigational guanylate cyclase-C (GC-C) receptor agonist for the treatment of irritable bowel syndrome with constipation (IBS-C). Once approved, linaclotide will be marketed in Europe under the trademark Constella®.
› Verified 4 days ago
| Provider Name | Professional Speech And Hearing Specialists, Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1790907145 PECOS PAC ID: 2264507714 Enrollment ID: O20080818000360 |
News Archive
Tens of thousands of Massachusetts residents depend on home care to support their health as they age or cope with physical challenges. That care often requires close personal contact, increasing the risk of contracting COVID-19 among both home-care clients and the aides who provide their care.
Before you plop in front of the television for a day of football, pizza and beer, you might consider this: New research shows that in young adults, decades of hard-won progress in reducing the risk of heart disease appears to be stalling, as recent death rates from coronary disease remain almost unchanged in young men and may even be increasing in women.
Metal-binding agents rubbed into the skin, prescribed by some alternative practitioners for the treatment of autism, are not absorbed and therefore are unlikely to be effective at helping the body excrete excess mercury. The study by Jennifer Cohen and Michelle Ruha from Banner Good Samaritan Medical Center in the US, and their colleagues, provides evidence against the use of these treatments in children with autism.
Today, Intercell AG announced its financial results for Q2 and H1 2010.IXIARO/JESPECT sales increased significantly from EUR 2.4m in Q2 2009 to EUR 5.2m in Q2 2010 Continued focus on growing marketing and sales of product in traveler and military markets
Almirall, S.A. announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for linaclotide, an investigational guanylate cyclase-C (GC-C) receptor agonist for the treatment of irritable bowel syndrome with constipation (IBS-C). Once approved, linaclotide will be marketed in Europe under the trademark Constella®.
› Verified 4 days ago
| Provider Name | Professional Hearing Group Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1053056846 PECOS PAC ID: 8325413677 Enrollment ID: O20230419000445 |
News Archive
Tens of thousands of Massachusetts residents depend on home care to support their health as they age or cope with physical challenges. That care often requires close personal contact, increasing the risk of contracting COVID-19 among both home-care clients and the aides who provide their care.
Before you plop in front of the television for a day of football, pizza and beer, you might consider this: New research shows that in young adults, decades of hard-won progress in reducing the risk of heart disease appears to be stalling, as recent death rates from coronary disease remain almost unchanged in young men and may even be increasing in women.
Metal-binding agents rubbed into the skin, prescribed by some alternative practitioners for the treatment of autism, are not absorbed and therefore are unlikely to be effective at helping the body excrete excess mercury. The study by Jennifer Cohen and Michelle Ruha from Banner Good Samaritan Medical Center in the US, and their colleagues, provides evidence against the use of these treatments in children with autism.
Today, Intercell AG announced its financial results for Q2 and H1 2010.IXIARO/JESPECT sales increased significantly from EUR 2.4m in Q2 2009 to EUR 5.2m in Q2 2010 Continued focus on growing marketing and sales of product in traveler and military markets
Almirall, S.A. announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for linaclotide, an investigational guanylate cyclase-C (GC-C) receptor agonist for the treatment of irritable bowel syndrome with constipation (IBS-C). Once approved, linaclotide will be marketed in Europe under the trademark Constella®.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tabatha Trapp Mccallum, AUD 40 Sw 12th St, C-201, Ocala, FL 34471-6525 Ph: (352) 351-3977 | Dr Tabatha Trapp Mccallum, AUD 40 Sw 12th St, C-201, Ocala, FL 34471-6525 Ph: (352) 351-3977 |
News Archive
Tens of thousands of Massachusetts residents depend on home care to support their health as they age or cope with physical challenges. That care often requires close personal contact, increasing the risk of contracting COVID-19 among both home-care clients and the aides who provide their care.
Before you plop in front of the television for a day of football, pizza and beer, you might consider this: New research shows that in young adults, decades of hard-won progress in reducing the risk of heart disease appears to be stalling, as recent death rates from coronary disease remain almost unchanged in young men and may even be increasing in women.
Metal-binding agents rubbed into the skin, prescribed by some alternative practitioners for the treatment of autism, are not absorbed and therefore are unlikely to be effective at helping the body excrete excess mercury. The study by Jennifer Cohen and Michelle Ruha from Banner Good Samaritan Medical Center in the US, and their colleagues, provides evidence against the use of these treatments in children with autism.
Today, Intercell AG announced its financial results for Q2 and H1 2010.IXIARO/JESPECT sales increased significantly from EUR 2.4m in Q2 2009 to EUR 5.2m in Q2 2010 Continued focus on growing marketing and sales of product in traveler and military markets
Almirall, S.A. announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for linaclotide, an investigational guanylate cyclase-C (GC-C) receptor agonist for the treatment of irritable bowel syndrome with constipation (IBS-C). Once approved, linaclotide will be marketed in Europe under the trademark Constella®.
› Verified 4 days ago
Mrs. Leigh Ann Watts, AUD, CCC-A Audiologist Medicare: Accepting Medicare Assignments Practice Location: 1847 Sw 1st Ave, Ocala, FL 34474 Phone: 352-629-4418 Fax: 352-351-4522 | |
Dr. Shon A Murray, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 3615 Se 45th Avenue, Ocala, FL 34480 Phone: 352-266-6468 Fax: 352-390-6184 | |
Advanced Hearing Group, Llc Audiologist Medicare: Not Enrolled in Medicare Practice Location: 8602 Sw Highway 200 Ste E, Ocala, FL 34481 Phone: 352-873-1722 Fax: 352-873-1622 | |
Quality Hearing Audiologist Medicare: Not Enrolled in Medicare Practice Location: 1111 Ne 25th Ave, Suite 204, Ocala, FL 34470 Phone: 352-671-3277 Fax: 352-671-8164 | |
Lindsey Lagalante, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 40 Sw 12th St Ste C201, Ocala, FL 34471 Phone: 352-351-3977 Fax: 352-351-8642 | |
Dawn M. Dion, AU.D Audiologist Medicare: Medicare Enrolled Practice Location: 40 Sw 12th St, Ste 201c, Ocala, FL 34471 Phone: 352-351-3977 Fax: 352-351-8642 |